Treatment of Autoimmune Diseases Having a Pathogenic T Cell State
Summary
The Brigham and Women's Hospital, Inc. filed patent application US20260108606A1 on October 23, 2025, covering methods of treating autoimmune and inflammatory diseases by targeting pathogenic immune cell states. Inventors Ana Carrizosa Anderson and Davide Mangani disclosed novel gene dependencies in pathogenic immune cells and methods for modifying immune cells characterized by that state. CPC classifications span A61K, A61P 37/06, C12N 15/85, and C12N 2800/107.
“The subject matter disclosed herein is generally directed to methods of treating autoimmune and inflammatory diseases characterized by a pathogenic immune cell state.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
The Brigham and Women's Hospital, Inc. has published a patent application (US20260108606A1) disclosing methods for treating autoimmune and inflammatory diseases characterized by a pathogenic immune cell state. The application identifies novel gene dependencies in pathogenic immune cells and discloses techniques for modifying such cells. The filing covers CPC classifications relevant to pharmaceutical compositions (A61K), immunology therapeutics (A61P 37/06), and genetic modification methods (C12N 15/85).
For biotechnology and pharmaceutical companies developing autoimmune disease therapies, this application signals potential gene-level targets for immune cell modification. Companies in the autoimmune therapeutics space should monitor the prosecution of this application for claims that may affect freedom-to-operate assessments for similar T cell targeting approaches.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TREATMENT OF AUTOIMMUNE DISEASES HAVING A PATHOGENIC T CELL STATE
Application US20260108606A1 Kind: A1 Apr 23, 2026
Assignee
THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Inventors
Ana Carrizosa ANDERSON, Davide MANGANI
Abstract
The subject matter disclosed herein is generally directed to methods of treating autoimmune and inflammatory diseases characterized by a pathogenic immune cell state. Disclosed are novel gene dependencies in the pathogenic immune cell state. Also, disclosed are methods for modifying immune cells characterized by the pathogenic immune cell state.
CPC Classifications
A61K 40/36 A61K 40/11 A61P 37/06 C12N 15/85 C12N 2800/107
Filing Date
2025-10-23
Application No.
19367293
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.